Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04319900|
Recruitment Status : Unknown
Verified March 2020 by Lihong Liu, Beijing Chao Yang Hospital.
Recruitment status was: Recruiting
First Posted : March 24, 2020
Last Update Posted : March 24, 2020
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
This study is a multi-centered, three-armed, randomized, double-blinded, controlled study, namely, the oral trial drug favipiravir tablets plus chloroquine phosphatetablets tablets group (combined group), the oral trial drug favipiravir tablets group (pirovir group), and the oral placebo treatment group (control group). The total number of enrolled cases in this study was set at 150.
During the treatment, the clinical data of the subjects were collected, the changes of viral load and biochemical indicators were detected, and the outcome of the subjects was monitored.
The main indicators of efficacy include improvement or recovery of respiratory symptoms and viral nucleic acid shedding. The rate of progression to severe disease, duration of fever, peripheral blood index and improvement time of pulmonary imaging were the secondary indicators to evaluate the efficacy.
Statistical analysis was performed at the middle and final stages of the study to evaluate the efficacy and safety of favipiravir tablets combined with chloroquine phosphatetablets tablets in the treatment of novel coronavirus pneumonia.
|Condition or disease||Intervention/treatment||Phase|
|Novel Coronavirus Pnuemonia||Drug: favipiravir tablets+chloroquine phosphatetablets tablets Drug: Favipiravir tablets Drug: Placebo||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||150 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Care Provider)|
|Official Title:||Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia|
|Actual Study Start Date :||March 5, 2020|
|Estimated Primary Completion Date :||April 30, 2020|
|Estimated Study Completion Date :||June 25, 2020|
Experimental: favipiravir tablets+chloroquine phosphatetablets tablets group
favipiravir tablets+chloroquine phosphatetablets tablets
Drug: favipiravir tablets+chloroquine phosphatetablets tablets
Favipiravir tablets+ chloroquine phosphate tablets group: 50 patients (anticipated).
Favipiravir tablets: On the first day, once for 1600 mg, twice a day; From the 2nd day to the 10th day, once for 600 mg, twice a day; maximum of 10 days for oral administration of the drug.
Chloroquine phosphate tablets: a total of 1000mg split into two times on day one; from day two to day three, 500mg, once a day; from day four to day ten, 250mg, once a day. Maximum of 10 days for oral administration of the drug.
Experimental: favipiravir tablets group
Drug: Favipiravir tablets
Favipiravir tablets group: 50 patients (anticipated). Favipiravir tablets: On the first day, once for 1600 mg, twice a day; From the 2nd day to the 10th day, once for 600 mg, twice a day; maximum of 10 days for oral administration of the drug.
Placebo Comparator: placebo treatment group
Placebo for favipiravir tablets is produced by Zhejiang Haizheng pharmaceutical co, LTD, batch no. 21812252, Placebo for chloroquine phosphate tablets is produced by the Chinese people's liberation army academy of military science military medical research institute production, batch no. 20200215. All placebos were complied with the quality inspection standard.
- Time of Improvement or recovery of respiratory symptoms [ Time Frame: 10 days during the intervention period ]Time of improvement or recovery of respiratory symptoms
- Number of days virus nucleic acid shedding [ Time Frame: 10 days during the intervention period ]Number of days from positive to negative for test of swab or sputum virus nucleic acid
- Frequency of Improvement or recovery of respiratory symptoms [ Time Frame: 10 days during the intervention period ]Frequency of improvement or recovery of respiratory symptoms
- Duration of fever [ Time Frame: 10 days during the intervention period ]Duration of fever after recruitment
- Frequencies of progression to severe illness [ Time Frame: 10 days during the intervention period ]Disease is defined as severe if it meets any of the following criteria: 1.Respiratory rate ≥30/min; 2. Oxygen saturation ≤93%; 3. Arterial partial oxygen pressure (PaO2)/oxygen absorption concentration (FiO2) ≤300 mmHg (1 mmHg=0.133 kPa)
- Time of improvement of pulmonary imaging [ Time Frame: 10 days during the intervention period ]Time of improvement of pulmonary imaging
- Peripheral blood c-reactive protein concentration [ Time Frame: day-1,3,7,14 after the intervention period ]Peripheral blood c-reactive protein concentration
- Absolute value of peripheral blood lymphocytes [ Time Frame: day-1,3,7,14 after the intervention period ]Absolute value of peripheral blood lymphocytes
- percentage of peripheral blood lymphocytes [ Time Frame: day-1,3,7,14 after the intervention period ]percentage of peripheral blood lymphocytes
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 75 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Male and female, 18-75 years old
- Patients previously diagnosed with novel coronavirus pneumonia: the course of illness is no more than 14 days; if the course of the disease was more than 14 days, patient meets one of the following conditions can also be included in the group: (1) No apparent absorption or progression of chest radiograph was observed within 7 days; (2) respiratory symptoms (chest tightness, or cough, or breathing difficulties); (3) Test for viral nucleic acid positive within 3 days.
- informed consent should be signed by the participate or an authorized agent
- Agree to clinical samples collection
- Female or male subjects of childbearing age agree to take effective contraceptive measures within 3 months of the last oral medication to ensure that female or male partners of childbearing age do not become pregnant
- Severe vomiting or difficulty ingesting medication
- Woman who are pregnant or during lactation
- Patients received lopinavir/ridonavir, ribavirin, interferon and monoclonal antibody specific antiviral drugs three days before enrollment
- Cases of respiratory failure requiring mechanical ventilation
- Combined with other organ failure and requires ICU care
- Clinical prognostic non-survival, palliative care, or in deep coma and no have response to supportive treatment within three hours of admission
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04319900
|Contact: Shumin Wang, Phd.||+86 email@example.com|
|Beijing Chaoyang hospital||Recruiting|
|Beijing, Beijing, China, 100020|
|Contact: Shumin Wang, Phd. +86 13488760399 firstname.lastname@example.org|
|Responsible Party:||Lihong Liu, Prof., Beijing Chao Yang Hospital|
|Other Study ID Numbers:||
|First Posted:||March 24, 2020 Key Record Dates|
|Last Update Posted:||March 24, 2020|
|Last Verified:||March 2020|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Respiratory Tract Infections
Respiratory Tract Diseases
RNA Virus Infections